MiR-27a As A Preliminary Study Of The Early Diagnosis Of Prostate Cancer Marker

Objective：Detection prostatitis, benign prostatic hyperplasia, prostate cancer androgen,PSA, MiRNA-27a levels and to analyze the correlation of the three, explore therelationship between clinicopathological features MiRNA-27a between content andprostate cancer.Materials and Methods:Collection of male prostatitis patients18-65years (labeled A control groups,60cases), benign prostatic hyperplasia patients aged≥50years (group B marked asexperimental group,60cases), diagnosed with prostate cancer (I-IV) patients aged≥50years (group C labeled experimental group2, n=34) before surgery serum,and serum prostate cancer surgery, the patients in each group were newly diagnosed,previously untreated line chemotherapy, age≥50years of age, tumor stage byAJCC latest standards, prostatitis patients were performed blood, biochemical, PSA,abdominal ultrasound, digital rectal examination to check no abnormalities, and noprevious history of malignancy; using RT-PCR analysis of blood and tissuespecimens MiRNA-27a, and the use of radioimmunoassay kits detect the malehormone, ELISA to detect PSA, correlation analysis and correlation with clinicalfeatures between the three between.After VCaP prostate cancer cells and inhibits VCaP prostate cancer cells: both10%DMEM medium containing fetal bovine serum,37℃,5%CO2incubator,culture passaged to stabilize in the logarithmic growth phase, the use of hormone-inhibiting hormone VCaP prostate cancer treatment; detected after hormonesuppression VCaP appreciation rate of prostate cancer cells using MTT cell counting;Annexin-V/PI method using flow cytometry apoptosis rate after hormone suppressionof prostate cancer cells; cell scratch assay hormone suppression after exercisecapacity after VCaP prostate cancer cells; after Transwell migration assay hormone suppression after the invasion ability of prostate cancer cells; RT-PCR to detect thehormone suppression after VCaP prostate cancer MiRNA-27a of expression.Results:1． Prostate cancer patients (I-IV stage) than non-prostate cancer patients(including normal and prostatitis, benign prostatic hyperplasia) MiRNA-27a hassignificantly changed (P <0.01);2．In patients with prostate cancer (I-IV stage) in, MiRNA-27a with age (|r|=0.7541), TNM staging (|r|=0.9663), prostate tumor size (|r|=0.9216) correlationcoefficients were greater than0.7, indicating a high degree of linearity betweenMiRNA-27a and the positive correlation between these indicators;3．PSA in the gray zone (4ng/ml≤PSA≤10ng/ml) in MiRNA-27a levelswere significantly different in prostate cancer and non-prostate cancer;4．Androgen-dependent prostate cancer cell line experiments intervention VCaphormone levels, inhibiting the expression of its MiRNA-27a, the results showedsignificantly inhibited cell growth, value-added rate decreased apoptosis rateincreased, decreased exercise capacity, decreased invasiveness.Conclusion:1．In patients with prostate cancer (I-IV) in, MiRNA-27a concentration andtumor stage and size of the prostate cancer tissue has a positive correlation betweenprostate cancer and non-prostate cancer patients MiRNA-27a were significantlydifferent;2．PSA in the gray zone for prostate patients, MiRNA-27a is a good sensitivityand specificity than the new indicators, in limited cases, the changes and pathologicalfindings MiRNA-27a compliance rate of100%;3．Changes MiRNA-27a levels can improve early detection of PSA in the grayzone of asymptomatic patients with prostate cancer;4．Inhibiting androgen, can significantly reduce the hormone-dependent prostate cells Vcap content MiRNA-27a, which significantly reduced invasiveness andproliferation rate, cell cycle inhibition in a non-proliferative state.